曲妥珠单抗联合多西紫杉醇在HER-2阳性晚期乳腺癌中的应用  

Application of Trastuzumab combined Docetaxel in Treatment of HER-2 Positive Advanced Breast Cancer

作　　者：宋敏[1] 赵静[1] 陈丽艳[1] 李景[1] 昂冰[1] SONG Min ZHAO Jing CHEN Li-yan LI Jing ANG Bing(Department of Oncology, Huludao Center Hospital of Liaoning Province, Huludao, Liaoning, 125001, China)

机构地区：[1]辽宁省葫芦岛市中心医院肿瘤科,辽宁葫芦岛125001

出　　处：《现代生物医学进展》2017年第6期1152-1155,共4页Progress in Modern Biomedicine

摘　　要：目的:探讨曲妥珠单抗联合多西紫杉醇在HER-2阳性晚期乳腺癌中的应用。方法:收取2010年2月至2016年1月我院收治的82例HER-2阳性晚期乳腺癌患者作为研究对象,根据不同治疗方案分为观察组及对照组。观察组43例患者给予曲妥珠单抗联合多西紫杉醇治疗,多西紫杉醇以3周为1个周期连续用药4个周期,曲妥珠单抗连续使用8周~52周。对照组39例患者只给予曲妥珠单抗单药治疗。对两组患者临床疗效、临床受益反应指数以及不良反应发生情况进行观察与比较。结果:51P1察组总有效率(60.47%)高于对照组(43.59%),但差异无统计学意义(P>0.05)。观察组疾病控制率(90.70%)显著高于对照组(71.79%),差异有统计学意义(P<0.05)。观察组临床受益反应有效率(76.74%)显著高于对照组(41.03%)差异有统计学意义(P<0.05)。两组患者不良反应无显著差异(P>0.05)。结论:曲妥珠单抗联合多西紫杉醇对于HER-2阳性晚期乳腺癌有较好的临床疗效及安全性,患者临床受益高。Objective：To explore the application of trastuzumab combined docetaxel in treatment of HER-2 positive advanced breast cancer.Methods：82 patients with HER-2 positive advanced breast cancer accepted in our hospital from February 2010 to January2016 were selected and divided into observation group and control group according to different methods of treatment.43 patients in observation group were given trastuzumab for 8 weeks to 52 weeks combined docetaxel for 4 periods β weeks a period）,and 39 patients in control group were given trastuzumab only.Then the clinical efficacy,clinical benefit response rate and adverse reaction rate of two groups were observed and compared.Results：The total efficacy of observation group（60.47%） was higher than that of control group（43.59%） without statistically significance（P〉0.05）.The diseases control rate of observation group（90.70%） was obviously higher than that of control group（71.79%） with statistically difference（P〈0.05）.The clinical benefit response rate of observation group（76.74%）was higher than that of control group（41.03%） with statistically significance（P〈0.05）.The rate of adverse reaction of two groups had no difference（P〉0.05）.Conclusions：Trastuzumab combined docetaxel has good efficacy and safety in treatment of HER-2 positive advanced breast cancer,and it can also improve the clinical benefit response rate.

关 键 词：HER-2阳性 乳腺癌 曲妥珠单抗 多西紫杉醇 

分 类 号：R737.9[医药卫生—肿瘤]